Allogene Therapeutics Reports Q3 2026 Net Loss of $50.4 Million

PUBT · 5d ago
Allogene Therapeutics Reports Q3 2026 Net Loss of $50.4 Million
  • Allogene Therapeutics reported a third-quarter 2026 net loss of $50.4 million.
  • Cash, cash equivalents and investments totaled $388.9 million at September 30, supporting a projected cash runway into 2029.
  • The next ALPHA3 clinical update is expected in mid-2027, with trial enrollment completion anticipated by year-end 2027.
  • Updated ALLO-329 autoimmune disease trial results are scheduled for presentation November 9, 2026.
  • Projected 2026 GAAP operating expenses total approximately $225 million, including about $35 million in non-cash stock-based compensation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allogene Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611051602PRIMZONEFULLFEED9870831) on November 05, 2026, and is solely responsible for the information contained therein.